Navigation Links
Amylin and Lilly Set Date and Time for Conference Call
Date:8/25/2008

Companies Will Discuss Recent FDA Advisory Regarding BYETTA

SAN DIEGO, Aug. 25 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) will Web cast a conference call on Tuesday, August 26 at 5:00 p.m. ET/2:00 p.m. PT to discuss the recent FDA advisory on BYETTA(R) (exenatide) injection. Leading the call for Amylin will be Daniel M. Bradbury, Amylin's President and Chief Executive Officer and Orville G. Kolterman, M.D., Amylin's Senior Vice President of Research and Development. Leading the call for Lilly will be Donald Therasse, M.D., Lilly's Vice President of Global Patient Safety.

The call will be Web cast live through Amylin's corporate Web site and a recording will be made available following the close of the call. To access the Web cast, please log on to http://www.amylin.com approximately fifteen minutes prior to the call to register, download and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (866) 814-1915 (domestic) or (703) 639-1359 (international), passcode 1277182. A replay of the call will also be available by phone through September 26, 2008 beginning approximately one hour after the close of the call and can be accessed at (888) 266-2081 (domestic) or (703) 925-2533 (international), passcode 1277182.

About Amylin and Lilly

Amylin Pharmaceuticals is a biopharmaceutical company committed to i
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
2. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
3. Amylin Pharmaceuticals Reports Third Quarter Financial Results
4. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
5. Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
6. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
7. Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
8. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amylin Pharmaceuticals to Webcast First Quarter Results
10. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
11. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...S, Ohio, Nov. 30 The Ohio Capital ...nation,s first minority business early-stage capit...cember 3, is called "Transforming the Landscape of...age Capital Summit." It will feature several speak...s leaders and local minority entrepreneurs. ,,...
(Date:11/30/2009)...K, Nov. 30 The Michael ...today announced $1.5 million in total awards to si...sease-modifying therapies for Parkinson,s disease....es to Drug Discovery for Parkinson,s Disease prog...n, plc (NYSE: ELN ), a neuroscience-based biotec...
(Date:11/30/2009)...Nov. 30 Dr. Jessica Torrente, Assi...University Medical Center in Washington, D.C., dem...ic Gamma Imaging (BSGI) in clinical practice as an...ast cancer today at the annual meeting of the Radi...he purpose of the exhibit was to demonstrate how B...
(Date:11/30/2009)... PDS, a leader in providing smart and efficie...s Pajama Pathology®, evolutionizing work-from-...old standard’ software used by 8 of the Top ... ‘cost per slide’ basis. , ... 30, 2009 -- PDS has announced another evolution i...
Breaking Biology Technology:Ohio Capital Fund Announces Sponsorship of Minority Business Conference 2The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 2The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 3Breast-Specific Gamma Imaging In Clinical Practice as an Adjunct Imaging Modality for Diagnosis of Breast Cancer 2Pajama Pathology -- the New Wave of Preclinical Pathology Embraced by PDS 2Pajama Pathology -- the New Wave of Preclinical Pathology Embraced by PDS 3
...Simcere Pharmaceutical,Group (NYSE: SCR ), a lead...harmaceuticals and innovative anti-cancer pharmace...nced today that it intends to release its 2008,thi...before the market,opens in the United States. Simc...hief financial officer, Frank Zhigang Zhao, will h...
...20) -- Nektar Therapeutics (Nasdaq: NKTR ) today ...rom Nektar specific pulmonary delivery,assets, tec...n in cash., "This agreement will allow us to focu...tics using our PEGylation and conjugate chemistry-...sident and CEO Howard W. Robin.,"The transaction a...
... defects, bulk crystalline materials never achieve...hand, are so small there,s no room for defects. ("...er.) Yet while nanocrystalline materials may appro...most nanostructures have shown only a limited abil...y fail. Overcoming this limitation could lead to g...
Other Biology Technology:Simcere Pharmaceutical Group to Announce Third Quarter 2008 Earnings on Thursday, November 6, 2008 2Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder 2Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder 3Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder 4Engineering nanoparticles for maximum strength 2Engineering nanoparticles for maximum strength 3Engineering nanoparticles for maximum strength 4
(Date:11/26/2009)...2009) Whitehead researchers have developed a new ... specific genes and proteins used by pathogens, ac...uman cell cultures genes are present in two copies...other. Gene inactivation by mutation is therefore ...the second copy usually remains active and takes o...
(Date:11/25/2009)...he California Institute of Technology (Caltech) ha...behavior in the fruit fly, Drosophila melanogaste...he relationship between the neurotransmitter dopam...ADHD), are described in the December issue of the ...ins only about 20,000 neurons and has long been co...
(Date:11/25/2009)...police officers and ambulance workers faced a terr...plex. They battled to save people from the collaps...ires and evacuated as many people as they could in...e. And making their jobs even harder was the probl...their relatives jammed mobile networks with calls ...
Breaking Biology News(10 mins):Knockouts in human cells point to pathogenic targets 2Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 2Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 3Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 4Magic box for mission impossible 2Magic box for mission impossible 3Industry Veterans Rash and Rutledge Launch RegionalCare Hospital Partners to Acquire and Operate Hospitals in Non Urban Markets 51850 1Industry Veterans Rash and Rutledge Launch RegionalCare Hospital Partners to Acquire and Operate Hospitals in Non Urban Markets 51850 2Industry Veterans Rash and Rutledge Launch RegionalCare Hospital Partners to Acquire and Operate Hospitals in Non Urban Markets 51850 3Industry Veterans Rash and Rutledge Launch RegionalCare Hospital Partners to Acquire and Operate Hospitals in Non Urban Markets 51850 4Pamela Davis Announced as Recipient of ACFE Sentinel Award 51847 1Pamela Davis Announced as Recipient of ACFE Sentinel Award 51847 2Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL 28R 29 for Treatment of Advanced Breast Cancer 51845 1Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL 28R 29 for Treatment of Advanced Breast Cancer 51845 2Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL 28R 29 for Treatment of Advanced Breast Cancer 51845 3Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL 28R 29 for Treatment of Advanced Breast Cancer 51845 4Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL 28R 29 for Treatment of Advanced Breast Cancer 51845 5Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL 28R 29 for Treatment of Advanced Breast Cancer 51845 6
...A&M University and The University of Glasgow V...aturally occurring endogenous retroviruses are req... class of endogenous retroviruses, known as endoge...ovirus or enJSRVs, are critical during the early p...lop. , Retroviruses, such as human immunodeficie...
...ns Bloomberg School of Public Health, the Imperial...dia, in Lima, Peru, and other institutions have de...est. The test, called microscopic-observation drug... and cheaper to perform than current culture-based...2006, issue of the New England Journal of Medicine...
...devised a way to use a brief burst of electricity ...iny gold launch pad. The technique could someday b...mmand from a chip implanted in the body. The metho...quire the controlled release of extremely small qu...ibed Sept. 10 in a presentation by Peter C. Searso...
Other Biology News:Researchers discover that sheep need retroviruses for reproduction 2Faster, more accurate tuberculosis test developed 2Electric jolt triggers release of biomolecules, nanoparticles 2
CORNING ROLLER BOTTLE WITH CELLBIND, 1700CM2, STERILE from Sigma-Aldrich
HP Guaranteed siRNA from QIAGEN
...or heterologous protein expression in the Drosoph...s derived from a primary culture of late stage (20...1). This versatile cell line grows rapidly at roo... suspension culture. S2 cells are available froze...
..., we in-troduced a new concept, namely production ...tional level at the T7 phage promoter, and (ii) at...id copy number, The main advantage of our dual-con...cally all of the outstanding features of the pET v...
Biology Products: